[Maribavir Treatment for Refractory and Drug-intolerant Cytomegalovirus Viremia and Disease After Allogeneic Hematopoietic Stem Cell Transplantation: a Clinical Analysis of 25 Cases]

Overview

Journal Zhonghua Xue Ye Xue Za Zhi

Specialty Hematology

Date 2025 Jan 2

PMID 39746694

Authors

W Ma

Z J Wei

Y Lu

J P Zhang

R J Sun

M Xiong

J R Zhou

L Dong

S Xue

X Y Cao

Affiliations

Soon will be listed here.

Abstract

To investigate the safety and efficacy of maribavir for the treatment of CMV viremia and CMV disease refractory or intolerant to conventional antiviral drugs after allogeneic hematopoietic stem cell transplantation (allo-HSCT) . This study retrospectively analyzed the clinical characteristics and outcomes of CMV viremia and CMV disease refractory or intolerant to conventional antiviral drugs after allo-HSCT treated with maribavir at Hebei Yanda Lu Daopei Hospital from April 2024 to September 2024. A total of 25 patients received maribavir, including 21 haploidentical transplants, two sibling HLA-matched transplants, and 2 HLA-matched unrelated transplants. Among them, 21, 2, and 2 patients received the first, second, and third transplants, respectively. The median time to the onset of CMV viremia and CMV disease was 120.5 (6-298) days post-transplantation. The median peak plasma CMV copy number was 6 400 copies/ml (range: 1 100-650 000 copies/ml). Six patients were diagnosed with CMV disease. Maribavir was administered after a median of 9.5 (1-41) days after CMV infection. The median duration of maribavir administration was 11.5 (6-43) days. Post-treatment, maribavir was effective in 25 (100%) patients. Two patients experienced grade 1 taste abnormalities, and one patient experienced grade 2 myelosuppression. The application of maribavir after allo-HSCT for treating refractory, drug-intolerant CMV viremia and CMV disease is safe and effective.

References

Schoettler M, Carreras E, Cho B, Dandoy C, Ho V, Jodele S . Harmonizing Definitions for Diagnostic Criteria and Prognostic Assessment of Transplantation-Associated Thrombotic Microangiopathy: A Report on Behalf of the European Society for Blood and Marrow Transplantation, American Society for Transplantation.... Transplant Cell Ther. 2022; 29(3):151-163. PMC: 10119629. DOI: 10.1016/j.jtct.2022.11.015. View

Shen M, Hong S, Wang J, Zhang X, Xu L, Wang Y . A Predicted Model for Refractory/Recurrent Cytomegalovirus Infection in Acute Leukemia Patients After Haploidentical Hematopoietic Stem Cell Transplantation. Front Cell Infect Microbiol. 2022; 12:862526. PMC: 8981086. DOI: 10.3389/fcimb.2022.862526. View

Bonatti H, Sifri C, Larcher C, Schneeberger S, Kotton C, Geltner C . Use of Cidofovir for Cytomegalovirus Disease Refractory to Ganciclovir in Solid Organ Recipients. Surg Infect (Larchmt). 2016; 18(2):128-136. DOI: 10.1089/sur.2015.266. View

Fisher J, Mulieri K, Finch E, Ericson J . Use of Maribavir for Multidrug Resistant Cytomegaloviremia in a Pediatric Oncology Patient. J Pediatr Hematol Oncol. 2024; 46(3):e244-e247. PMC: 10956659. DOI: 10.1097/MPH.0000000000002841. View

Yan C, Wang Y, Mo X, Sun Y, Wang F, Fu H . Incidence, risk factors, and outcomes of cytomegalovirus retinitis after haploidentical hematopoietic stem cell transplantation. Bone Marrow Transplant. 2020; 55(6):1147-1160. DOI: 10.1038/s41409-020-0790-z. View

Chen Y, Xu L, Liu K, Chen H, Chen Y, Zhang X . Risk factors for cytomegalovirus DNAemia following haploidentical stem cell transplantation and its association with host hepatitis B virus serostatus. J Clin Virol. 2016; 75:10-5. DOI: 10.1016/j.jcv.2015.12.003. View

Sun Y, Wang Y, Zhang X, Xu L, Liu K, Yan C . Virus reactivation and low dose of CD34+ cell, rather than haploidentical transplantation, were associated with secondary poor graft function within the first 100 days after allogeneic stem cell transplantation. Ann Hematol. 2019; 98(8):1877-1883. DOI: 10.1007/s00277-019-03715-w. View

Cantoni N, Hirsch H, Khanna N, Gerull S, Buser A, Bucher C . Evidence for a bidirectional relationship between cytomegalovirus replication and acute graft-versus-host disease. Biol Blood Marrow Transplant. 2010; 16(9):1309-14. DOI: 10.1016/j.bbmt.2010.03.020. View

Marty F, Ljungman P, Chemaly R, Maertens J, Dadwal S, Duarte R . Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation. N Engl J Med. 2017; 377(25):2433-2444. DOI: 10.1056/NEJMoa1706640. View

10.

Drew W, Miner R, Marousek G, Chou S . Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet. J Clin Virol. 2006; 37(2):124-7. DOI: 10.1016/j.jcv.2006.07.010. View

11.

Chou S, Wu J, Song K, Bo T . Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection. Antiviral Res. 2019; 172:104616. PMC: 6892599. DOI: 10.1016/j.antiviral.2019.104616. View

12.

Xuan L, Huang F, Fan Z, Zhou H, Zhang X, Yu G . Effects of intensified conditioning on Epstein-Barr virus and cytomegalovirus infections in allogeneic hematopoietic stem cell transplantation for hematological malignancies. J Hematol Oncol. 2012; 5:46. PMC: 3422173. DOI: 10.1186/1756-8722-5-46. View

13.

Meng X, Fu H, Zhu X, Wang J, Liu X, Yan C . Comparison of different cytomegalovirus diseases following haploidentical hematopoietic stem cell transplantation. Ann Hematol. 2020; 99(11):2659-2670. DOI: 10.1007/s00277-020-04201-4. View

14.

Gao L, Zhang C, Gao L, Liu Y, Su Y, Wang S . Favorable outcome of haploidentical hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia: a multicenter study in Southwest China. J Hematol Oncol. 2015; 8:90. PMC: 4515001. DOI: 10.1186/s13045-015-0186-5. View

15.

Goldsmith S, Abid M, Auletta J, Bashey A, Beitinjaneh A, Castillo P . Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis. Blood. 2021; 137(23):3291-3305. PMC: 8351903. DOI: 10.1182/blood.2020009362. View

16.

Fisher C, Knudsen J, Lease E, Jerome K, Rakita R, Boeckh M . Risk Factors and Outcomes of Ganciclovir-Resistant Cytomegalovirus Infection in Solid Organ Transplant Recipients. Clin Infect Dis. 2017; 65(1):57-63. PMC: 5848370. DOI: 10.1093/cid/cix259. View

17.

Yang D, Yao Y, Sun Y, Jiang E . Refractory cytomegalovirus infections in Chinese patients receiving allogeneic hematopoietic cell transplantation: a review of the literature. Front Immunol. 2024; 14:1287456. PMC: 10770847. DOI: 10.3389/fimmu.2023.1287456. View

18.

Lauruschkat C, Muchsin I, Rein A, Erhard F, Grathwohl D, Dolken L . Impaired T cells and "memory-like" NK-cell reconstitution is linked to late-onset HCMV reactivation after letermovir cessation. Blood Adv. 2024; 8(11):2967-2979. PMC: 11302378. DOI: 10.1182/bloodadvances.2023012008. View

19.

Malagola M, Radici V, Farina M, Pellizzeri S, Spoldi F, Morello E . CMV prophylaxis with letermovir significantly improves graft and relapse free survival following allogeneic stem cell transplantation. Bone Marrow Transplant. 2023; 59(1):138-140. PMC: 10781629. DOI: 10.1038/s41409-023-02124-y. View

20.

Chou S, Alain S, Cervera C, Chemaly R, Kotton C, Lundgren J . Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. J Infect Dis. 2023; 229(2):413-421. PMC: 10873177. DOI: 10.1093/infdis/jiad293. View